Prechemoradiotherapy Systemic Inflammation Response Index Stratifies Stage IIIB/C Non-Small-Cell Lung Cancer Patients into Three Prognostic Groups: A Propensity Score-Matching Analysis

<div>Comparative survival outcomes according to pretreatment SIRI groups (red line: SIRI &lt; 1.9 and dark blue line: SIRI ≥ 1.9): (a) progression-free survival; (b) overall survival.</div>

Journal of Oncology

fig2

Figure 2

Figure 2: Prechemoradiotherapy Systemic Inflammation Response Index Stratifies Stage IIIB/C Non-Small-Cell Lung Cancer Patients into Three Prognostic Groups: A Propensity Score-Matching Analysis 

Figure 2 | Prechemoradiotherapy Systemic Inflammation Response Index Stratifies Stage IIIB/C Non-Small-Cell Lung Cancer Patients into Three Prognostic Groups: A Propensity Score-Matching Analysis 